secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2024-01-22T23:59:59+00:00
Accession:  0001437749-24-001879
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera secures $26M total capital commitment: $6M upfront equity, $8M royalty monetization
--------------------------------------------------------------------------------

- $6M upfront equity from Nantahala Capital and Rosalind Advisors; $10M additional upon positive NEPHRO trial data, $2M if stock price >=$0.92 for 5 days.
- $8M non-dilutive from partial DSUVIA royalty monetization to XOMA; after specified return, Talphera shares DSUVIA royalties/milestones equally.
- Preliminary cash $9.4M at Dec 31, 2023; cash operating expenses $21-23M in 2024 including NEPHRO registration trial.
- Abhinav Jain of Nantahala Capital joins Board at closing.
- Existing warrants amended: exercise price reduced to $0.77/share for up to 5,882,356 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924001879/0001437749-24-001879-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924001879/acrx20240117c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-001879

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer